Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $49 to $52.
QIAGEN has updated its FY 2024 outlook based on the solid core business performance in the first half of the year, which was ab...
Qiagen (NYSE:QGEN) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.51 by 7.84 pe...
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced a partnership with the Snow Molecular Anthropology Lab at ...
Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:QGEN) from Peer Perform to Outperform and announces $50 price tar...
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with K...
CORRECTION : JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $...
JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54.
